Table 3.
Comparison of the Clinicopathologic Characteristics between the EBV-Positive and EBV-Negative Groups in Non-GCLS (n=920)
| Characteristics | EBV+ (n=32) | EBV– (n=888) | p-value |
|---|---|---|---|
| Age at diagnosis, yr | 59.9±9.9 | 58.6±12.0 | 0.533 |
| Male sex | 27 (84.4) | 550 (61.9) | 0.014 |
| Location of the tumor | 0.001 | ||
| Upper third | 11 (34.4) | 127 (14.3) | |
| Middle third | 13 (40.6) | 274 (30.9) | |
| Lower third | 8 (25.0) | 487 (54.8) | |
| Lesions | 0.127 | ||
| Single | 30 (93.8) | 872 (98.2) | |
| Multiple | 2 (6.3) | 16 (1.8) | |
| Tumor size, cm | 3.57±2.19 | 3.98±2.76 | 0.404 |
| Pathologic T stage | 0.498 | ||
| T1 | 23 (71.9) | 566 (63.7) | |
| T2 | 4 (12.5) | 97 (10.9) | |
| T3&T4 | 5 (15.6) | 225 (25.3) | |
| Pathologic N stage | 0.757 | ||
| N0 | 26 (81.3) | 628 (70.7) | |
| N1 | 2 (6.3) | 109 (12.3) | |
| N2 | 2 (6.3) | 68 (7.7) | |
| N3 | 2 (6.3) | 83 (9.3) | |
| Histology | 0.637 | ||
| WD/MD | 9 (28.1) | 315 (35.5) | |
| PD/SRC | 22 (68.8) | 534 (60.1) | |
| Others* | 1 (3.1) | 39 (4.4) | |
| HP infection | 0.477 | ||
| HP (+) | 20 (62.5) | 497 (56.0) | |
| HP (–) | 12 (37.5) | 391 (44.0) | |
| HER2 | 0.414 | ||
| Score 0 & 1 | 26 (81.3) | 750 (84.5) | |
| Score 2 | 2 (6.3) | 75 (8.4) | |
| Score 3 | 4 (12.5) | 63 (7.1) | |
| p53 | <0.001 | ||
| Negative | 0 | 158 (17.8) | |
| Overexpression | 2 (6.3) | 235 (26.5) | |
| Equivocal | 30 (93.8) | 495 (55.7) | |
| AJCC stage | 0.529 | ||
| I | 24 (75.0) | 597 (67.2) | |
| II | 5 (15.6) | 145 (16.3) | |
| III | 3 (9.4) | 146 (16.4) | |
| LVi | 7 (21.9) | 289 (32.5) | 0.250 |
| PNi | 5 (15.6) | 217 (24.5) | 0.299 |
| Adjuvant chemotherapy | 6 (18.8) | 227 (25.6) | 0.420 |
Data are presented as mean±SD or number (%).
EBV, Epstein-Barr virus; GCLS, gastric carcinoma with lymphoid stroma; T, tumor; N, node; WD, well differentiated; MD, moderate differentiated; PD, poorly differentiated; SRC, signet ring cell; HP, Helicobacter pylori; HER2, human epidermal growth factor receptor 2; AJCC, American Joint Committee on Cancer; LVi, lymphovascular invasion; PNi, perineural invasion.
*Others: mucinous adenocarcinoma, papillary adenocarcinoma, adenoneuroendocrine carcinoma.